

Title (en)
Oral recombinant lactobacilli vaccines

Title (de)
Oraler Impfstoff enthaltend rekombinanten Lactobacilli

Title (fr)
Vaccin oral contenant des Lactobacilli recombinés

Publication
EP 1084709 A9 20010516 (EN)

Application
EP 99203056 A 19990917

Priority
EP 99203056 A 19990917

Abstract (en)
[origin: EP1084709A1] The present invention relates to an oral vaccine comprising recombinant lactic acid bacteria expressing heterologous antigen in vivo intracellularly and/or the surface of the lactic acid bacterium as specific immunogenicity eliciting component for eliciting immunogenicity against the heterologous antigen, characterised in that the recombinant lactic acid bacterium is a Lactobacillus plantarum. Preferably, the recombinant Lactobacillus plantarum comprises an expression vector capable of expressing the heterologous antigen intracellularly and/or such that the heterologous antigen is exposed on the cell surface under conditions present in the gastrointestinal tract. The recombinant Lactobacillus plantarum is preferably a recombinant Lactobacillus plantarum 256. The invention also relates to a recombinant Lactobacillus plantarum, more specifically a recombinant strain of Lactobacillus plantarum 256, for use in the vaccines of the invention; as well as to an expression vector suitable for intracellular expression or exposure of a heterologous antigen encoded thereon, said expression vector providing expression in a Lactobacillus plantarum of the heterologous antigen under conditions existing in the gastrointestinal tract.

IPC 1-7
A61K 39/00; **C12N 15/74**

IPC 8 full level
C12N 15/09 (2006.01); **A61K 35/74** (2015.01); **A61K 35/747** (2015.01); **A61K 39/00** (2006.01); **A61K 48/00** (2006.01); **A61P 31/04** (2006.01); **A61P 31/10** (2006.01); **A61P 31/12** (2006.01); **A61P 33/02** (2006.01); **A61P 37/08** (2006.01); **C12N 1/21** (2006.01); **C12N 15/74** (2006.01); **C12R 1/25** (2006.01)

CPC (source: EP US)
A61K 35/747 (2013.01 - EP); **A61K 39/00** (2013.01 - EP US); **A61P 31/04** (2018.01 - EP); **A61P 31/10** (2018.01 - EP); **A61P 31/12** (2018.01 - EP); **A61P 33/02** (2018.01 - EP); **A61P 37/08** (2018.01 - EP); **C12N 15/746** (2013.01 - EP); **A61K 2039/523** (2013.01 - EP); **A61K 2039/542** (2013.01 - EP); **Y02A 50/30** (2018.01 - EP)

Cited by
EP1723965A1; US8821893B2; US8691214B2; KR20160037879A; EP3009149A4; US10314916B2; WO2006123230A3; WO2014047625A1; WO2005040387A1; WO2007106073A3; US8802419B2; US9138468B2; US9452205B2; US9931390B2; WO03063785A3; EP1523559A1

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
EP 1084709 A1 20010321; **EP 1084709 A9 20010516**; AP 2002002445 A0 20020331; AU 7433700 A 20010424; CA 2383433 A1 20010329; CN 1387442 A 20021225; EP 1212083 A1 20020612; IL 148713 A0 20020912; JP 2003509469 A 20030311; OA 12023 A 20060419; WO 0121200 A1 20010329; ZA 200201969 B 20030827

DOCDB simple family (application)
EP 99203056 A 19990917; AP 2002002445 A 20000918; AU 7433700 A 20000918; CA 2383433 A 20000918; CN 00815334 A 20000918; EP 00962689 A 20000918; GB 0003575 W 20000918; IL 14871300 A 20000918; JP 2001524624 A 20000918; OA 1200200076 A 20000918; ZA 200201969 A 20020308